InnoStar operates a cutting-edge Biomarker and Translational Research Platform designed to accelerate innovative drug development. Our platform delivers comprehensive, end-to-end biomarker services spanning discovery, validation, and clinical implementation.
By integrating cutting-edge technologies such as genomics, proteomics, and single-cell sequencing, the platform supports key aspects of drug development, including target identification, mechanism elucidation, patient stratification, and efficacy prediction. Utilizing high-throughput sequencing, multiplex immunohistochemistry (IHC) analysis, multiplex protein and cytokine detection, as well as flow cytometry, the platform enables precise biomarker screening and functional validation. This accelerates drug development, enhances clinical trial success rates, and provides scientific and technical support for companion diagnostic strategies in new drug development